Evidence map›Paper›PMID 33006554›Full record

ReviewJournal of clinical research in pediatric endocrinology2021

Important Tools for Use by Pediatric Endocrinologists in the Assessment of Short Stature

José I. Labarta, Michael B. Ranke, Mohamad Maghnie, David Martin, Laura Guazzarotti, Roland Pfäffle, Ekaterina Koledova, Jan M. Wit

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical research in pediatric endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 4 countries.

José I. LabartaUniversity of Zaragoza, Children’s Hospital Miguel Servet, Instituto de Investigación Sanitaria de Aragón, Unit of Endocrinology, Zaragoza, SpainORCID 0000-0003-2832-2266
Michael B. RankeUniversity of Tübingen, Children’s Hospital, Clinic of Pediatric Endocrinology, Tübingen, GermanyORCID 0000-0002-3855-6157
Mohamad MaghnieUniversity of Genova, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Genova, ItalyORCID 0000-0002-7183-5238
David MartinUniversity of Witten/Herdecke and Tübingen University, Tübingen, GermanyORCID 0000-0002-4279-3032
Laura GuazzarottiUniversity of Milan, Luigi Sacco Hospital, Clinic of Pediatric, Milan, ItalyORCID 0000-0002-5648-0109
Roland PfäffleUniversity of Leipzig, Department of Pediatrics, Leipzig, GermanyORCID 0000-0001-6754-3681
Ekaterina KoledovaGlobal Medical Affairs, Merck KGaA, Darmstadt, GermanyORCID 0000-0003-2572-9052
Jan M. WitLeiden University Medical Centre, Department of Paediatrics, Leiden, NetherlandsORCID 0000-0002-1715-5020
Istituto Giannina Gaslini · ITLeiden University · NLLeipzig University · DEMerck (Germany) · DEUniversidad de Zaragoza · ESUniversity Children's Hospital Tübingen · DEUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessment and management of children with growth failure has improved greatly over recent years. However, there remains a strong potential for further improvements by using novel digital techniques. A panel of experts discussed developments in digitalization of a number of important tools used by pediatric endocrinologists at the third 360° European Meeting on Growth and Endocrine Disorders, funded by Merck KGaA, Germany, and this review is based on those discussions. It was reported that electronic monitoring and new algorithms have been devised that are providing more sensitive referral for short stature. In addition, computer programs have improved ways in which diagnoses are coded for use by various groups including healthcare providers and government health systems. Innovative cranial imaging techniques have been devised that are considered safer than using gadolinium contrast agents and are also more sensitive and accurate. Deep-learning neural networks are changing the way that bone age and bone health are assessed, which are more objective than standard methodologies. Models for prediction of growth response to growth hormone (GH) treatment are being improved by applying novel artificial intelligence methods that can identify non-linear and linear factors that relate to response, providing more accurate predictions. Determination and interpretation of insulin-like growth factor-1 (IGF-1) levels are becoming more standardized and consistent, for evaluation across different patient groups, and computer-learning models indicate that baseline IGF-1 standard deviation score is among the most important indicators of GH therapy response. While physicians involved in child growth and treatment of disorders resulting in growth failure need to be aware of, and keep abreast of, these latest developments, treatment decisions and management should continue to be based on clinical decisions. New digital technologies and advancements in the field should be aimed at improving clinical decisions, making greater standardization of assessment and facilitating patient-centered approaches.

Indexed as

Artificial IntelligenceHuman Growth HormoneChildDwarfismEndocrinologyHumansPediatricsHuman Growth Hormonebone agecranial imaginggrowth hormone treatmentheight monitoringprediction modelsShort stature

Identifiers

PMID33006554
PMCPMC8186334
OpenAlexW3090511564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.